Sanofi

Electra Therapeutics' ELA026 becomes the first investigational therapy to receive both FDA Breakthrough Therapy designation and EMA Priority Medicines designation for secondary hemophagocytic lymphohistiocytosis (sHLH).

Sanofi's efdoralprin alfa demonstrated statistically significant superiority over standard plasma-derived therapy in the ElevAATe phase 2 study, meeting all primary and key secondary endpoints for alpha-1 antitrypsin deficiency emphysema treatment.

Merck KGaA's antibody-drug conjugate precemtabart tocentecan (Precem-TcT) demonstrated a 31% objective response rate in heavily pre-treated colorectal cancer patients at 2.8mg/kg dose during Phase I trials.

California becomes the first state to sell its own brand of generic insulin through the CalRx program, with five-pack insulin pens available for $55 starting January 1, 2025.

Over 35 CD40-targeted therapies are currently in clinical trials, with the first approval expected by 2027 according to new market research.

Researchers at Cincinnati Children's Hospital Medical Center, in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that integrates patient-specific genetics and immune responses to predict idiosyncratic drug-induced liver injury.

Post hoc analysis of pooled BOREAS and NOTUS phase 3 trials demonstrates dupilumab's consistent efficacy in reducing COPD exacerbations by 31-33% regardless of cardiovascular or metabolic disease history.

Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.

Ona Therapeutics has appointed Dr. Antoine Yver, a veteran with over 35 years of oncology drug development experience, as Chair of its Board of Directors to guide the company's transition to clinical-stage operations.

Innate Pharma will host an investor event on October 28, 2025, to discuss lacutamab's path to potential accelerated approval in Sézary syndrome based on Phase 2 TELLOMAK trial data.